Clinical Trial Update: a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease [Phase 1, Phase 2]

View source ↗

Summary

A BCMA-targeted Prime CAR-T cell therapy is being evaluated for relapsed/refractory multiple myeloma and plasma cell neoplasms in Phase 1/2 and is currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Neoplasm

Drugs mentioned

• BCMA-Targeted Prime CAR-T Cell Therapy (BCMA-targeted prime CAR-T cell therapy)

Snippet

Sponsor: Chongqing Precision Biotech Co., Ltd | Conditions: Multiple Myeloma, Neoplasm, Plasma Cell | Phase 1, Phase 2 | Status: RECRUITING